Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

Shanghai Stock Exchange 600613.SS

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT for the year ending December 31, 2023: USD 14.01 M

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT is USD 14.01 M for the year ending December 31, 2023, a 21.17% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT for the year ending December 31, 2022 was USD 11.56 M, a -32.22% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT for the year ending December 31, 2021 was USD 17.06 M, a 133.36% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT for the year ending December 31, 2020 was USD -51.13 M, a -397.00% change year over year.
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. EBIT for the year ending December 31, 2019 was USD 17.21 M, a -4.41% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shanghai Stock Exchange: 600613.SS

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.

CEO	Mr. Feng Bin
IPO Date	Aug. 20, 1992
Location	China
Headquarters	Changfa Tower
Employees	1,426
Sector	Healthcare
Industries Pharmaceuticals Drugstores & Retail Pharmacies Eyewear Non-Alcoholic Beverages Personal Care Soft Drinks & Sodas

Description

Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, tonic products, cold and cough, children's medicine, and anti-fungal drugs. Its products include prescription drugs and OTC products. The company was founded in 1992 and is based in Shanghai, China.

Key trends

Past 5 years